IDiyas

For the Inventor, By the Inventor

Hagen, Germany

Thomas Krahn

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 7.5

ph-index = 9

Forward Citations = 255(Granted Patents)


Location History:

  • D 51368 Leverkusen, DE (2009)
  • Hagen, DE (2001 - 2015)

Company Filing History:

goldMedal10 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
silverMedal4 out of 192 
 
Bayer Schering Pharma Ag
 patents
bronzeMedal3 out of 76 
 
Bayer Healthcare Aktiengesellschaft
 patents
4. 3 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
5. 1 out of 7 
 
Nmi Naturwissenschaftliches Und Medizinisches Institut an Der Universitat Tubingen
 patents
6. 1 out of 2 
 
Bayer Aktiengeselischaft
 patents
7. 1 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2001-2015

Loading Chart...
Loading Chart...
22 patents (USPTO):
1. 8957017 - Dipeptoid prodrugs and their use (2015-02-17),
2. 8703696 - Dipeptoid prodrugs and the use thereof (2014-04-22),
3. 8242281 - Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands (2012-08-14),
4. 7855219 - Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof (2010-12-21),
5. 7825255 - Adenosine receptor selective modulators (2010-11-02),
6. 7709504 - Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting (2010-05-04),
7. 7615376 - Masking background fluorescence and luminescence in the optical analysis of biomedical assays (2009-11-10),
8. 7504421 - Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use (2009-03-17),
9. 7138280 - Masking of the background fluorescence and luminescence in the optical analysis of biomedical assays (2006-11-21),
10. 7135486 - Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof (2006-11-14),
11. 7129255 - Substituted 2-carba-3,5-dicyano-4-aryl-6-aminopyridines and the use of the same as selective ligands of the adenosine receptor (2006-10-31),
12. 7125995 - Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS) (2006-10-24),
13. 7109218 - Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same (2006-09-19),
14. 7078417 - Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations (2006-07-18),
15. 7074780 - Substituted phenylcyclohexanecarboxamides and their use (2006-07-11),

Title: Innovations of Thomas Krahn: Pioneering Dipeptoid Prodrugs

Introduction

Thomas Krahn, a prolific inventor based in Hagen, Germany, has made significant contributions to the field of medicinal chemistry. With an impressive portfolio of 22 patents, Krahn's work primarily revolves around the development of dipeptoid prodrugs, which hold potential for treating various diseases, especially cardiovascular disorders.

Latest Patents

Among his latest patents are two notable applications regarding dipeptoid prodrugs. The first application discusses prodrug derivatives of a specified compound, detailing processes for their preparation and their application for the treatment and/or prophylaxis of diseases. The second application reiterates similar findings, emphasizing the potential medicinal uses of these prodrugs in combating cardiovascular disorders and their importance in the manufacture of related medicaments.

Career Highlights

Throughout his career, Krahn has been associated with prominent companies in the pharmaceutical industry, notably Bayer Aktiengesellschaft and Bayer Schering Pharma AG. His work at these institutions has allowed him to refine his expertise and innovate in the realm of drug development, contributing to numerous advancements in therapeutics.

Collaborations

Krahn has collaborated with various professionals in his field, including Ulrich Rosentreter and Nicole Diedrichs. These partnerships have likely bolstered his innovative capabilities, leading to the creation of impactful patents that enhance medical treatments.

Conclusion

Thomas Krahn stands out as a key inventor in the realm of medicinal discoveries, with his work in dipeptoid prodrugs paving the way for future advancements in cardiovascular treatment. His collaborations and employment with leading pharmaceutical companies underscore his vital role in shaping modern medicine through innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…